Literature DB >> 8916974

Mortality hazard functions as related to neutropenia at different times after marrow transplantation.

F Offner1, G Schoch, L D Fisher, B Torok-Storb, P J Martin.   

Abstract

We characterized the relationship between severe neutropenia and risk of death in 2,276 patients after marrow transplantation to define objective and clinically relevant criteria that could be used to judge the timing and potential value of interventions designed to improve survival in patients with delayed initial engraftment. Proportional hazard models were used to estimate the relative risk of death before day 100 among patients alive on any given day with an absolute neutrophil count (ANC) less than 100/microL compared with those alive on the same day with an ANC > or = 100/microL. Between day 10 and 14, the risk ratio remained close to 1.0, indicating that the risk of death before day 100 for patients with an ANC less than 100/microL was similar to that for patients with an ANC > or = 100/microL. Between day 15, when 38% of patients had an ANC less than 100/microL, and day 26, when 3.8% of patients had an ANC less than 100/microL, the risk ratio showed an overall upward trend, indicating that patients with an ANC less than 100/microL had a higher risk of death before day 100 than those with an ANC > or = 100/microL. Thereafter, the risk ratio fluctuated between 2.01 and 5.78, indicating consistently higher risks of mortality in patients with severe neutropenia. However, allogeneic and autologous transplant recipients each had distinctive risk ratio patterns. These results could be helpful in deciding the appropriate timing for treatment given to improve graft function after marrow transplantation.

Entities:  

Mesh:

Year:  1996        PMID: 8916974

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Choosing between GVHD and delayed engraftment.

Authors:  Paul J Martin
Journal:  Nat Med       Date:  2009-04       Impact factor: 53.440

Review 2.  Ex vivo expansion of human hematopoietic stem and progenitor cells.

Authors:  Ann Dahlberg; Colleen Delaney; Irwin D Bernstein
Journal:  Blood       Date:  2011-03-23       Impact factor: 22.113

3.  Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.

Authors:  Christopher G Kanakry; Paul V O'Donnell; Terry Furlong; Marcos J de Lima; Wei Wei; Marta Medeot; Marco Mielcarek; Richard E Champlin; Richard J Jones; Peter F Thall; Borje S Andersson; Leo Luznik
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

Review 4.  Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications.

Authors:  Koen Van Besien; Hongtao Liu; Nitin Jain; Wendy Stock; Andrew Artz
Journal:  Biol Blood Marrow Transplant       Date:  2012-11-08       Impact factor: 5.742

5.  Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model.

Authors:  Beining Guo; Kamilia Abdelraouf; Kimberly R Ledesma; Kai-Tai Chang; Michael Nikolaou; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

6.  Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution.

Authors:  Colleen Delaney; Shelly Heimfeld; Carolyn Brashem-Stein; Howard Voorhies; Ronald L Manger; Irwin D Bernstein
Journal:  Nat Med       Date:  2010-01-17       Impact factor: 53.440

7.  Initially fewer bloodstream infections for allogeneic vs. autologous stem-cell transplants in neutropenic patients.

Authors:  S Hieke; H Bertz; M Dettenkofer; M Schumacher; J Beyersmann
Journal:  Epidemiol Infect       Date:  2012-03-07       Impact factor: 4.434

Review 8.  Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.

Authors:  Susanne H C Baumeister; Benedetta Rambaldi; Roman M Shapiro; Rizwan Romee
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.